KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Current Assets: 2009-2024

Historic Current Assets for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $3.2 billion.

  • Biomarin Pharmaceutical's Current Assets rose 26.11% to $3.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 billion, marking a year-over-year increase of 26.11%. This contributed to the annual value of $3.2 billion for FY2024, which is 9.35% up from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Current Assets is $3.2 billion, which was up 9.35% from $3.0 billion recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Current Assets ranged from a high of $3.2 billion in FY2024 and a low of $2.3 billion during FY2021.
  • Its 3-year average for Current Assets is $3.0 billion, with a median of $3.0 billion in 2023.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Current Assets dropped by 2.90% in 2021 and then increased by 20.98% in 2022.
  • Over the past 5 years, Biomarin Pharmaceutical's Current Assets (Yearly) stood at $2.3 billion in 2020, then decreased by 2.90% to $2.3 billion in 2021, then climbed by 20.98% to $2.8 billion in 2022, then climbed by 7.44% to $3.0 billion in 2023, then grew by 9.35% to $3.2 billion in 2024.